NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $24.27 -0.43 (-1.74%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Anika Therapeutics Stock (NASDAQ:ANIK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Anika Therapeutics alerts:Sign Up Key Stats Today's Range$24.16▼$24.6450-Day Range$24.25▼$28.3152-Week Range$17.88▼$29.11Volume34,138 shsAverage Volume63,652 shsMarket Capitalization$354.03 millionP/E RatioN/ADividend YieldN/APrice Target$30.50Consensus RatingModerate Buy Company OverviewAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More… Next Week Elon Could Trigger a Boom in this Sub-$3 Stock (Ad)Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world… Click here to see the details and save your seat. Anika Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks82nd Percentile Overall ScoreANIK MarketRank™: Anika Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 327th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAnika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.10) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -4.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anika Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.71% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 0.50%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.6 / 5Environmental Score-2.12 Percentage of Shares Shorted4.71% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 0.50%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment1.63 News SentimentAnika Therapeutics has a news sentiment score of 1.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Anika Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for ANIK on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.86% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock News HeadlinesAvant Brands (OTCMKTS:AVTBF) and Anika Therapeutics (NASDAQ:ANIK) Financial ReviewSeptember 23, 2024 | americanbankingnews.comAdhesion Barrier Market to Reach $1.5 Billion, Globally, by 2033 at 7.8% CAGR: Allied Market ResearchSeptember 18, 2024 | finance.yahoo.comThe world’s smartest man is in their crosshairsElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 2, 2024 | Porter & Company (Ad)Anika Therapeutics Inc (ANIK) Stock Price Up 4.14% on Sep 17September 17, 2024 | gurufocus.comKids make Elliot Avenue Gazette front page newsSeptember 17, 2024 | msn.comAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 9, 2024 | globenewswire.comAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2024 | globenewswire.comGlobal Non-Steroidal Anti-Inflammatory Drugs Market is Expected to Showcase a Significant Growth at a CAGR of ~6% by 2030 | DelveInsightAugust 15, 2024 | finance.yahoo.comSee More Headlines ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $22.66 on January 1st, 2024. Since then, ANIK stock has increased by 7.1% and is now trading at $24.27. View the best growth stocks for 2024 here. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) released its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.24. The biotechnology company earned $41.92 million during the quarter, compared to analysts' expectations of $39.90 million. Anika Therapeutics had a negative net margin of 44.45% and a positive trailing twelve-month return on equity of 0.94%. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/08/2024Today10/01/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees357Year Founded1992Price Target and Rating Average Stock Price Target$30.50 High Stock Price Target$37.00 Low Stock Price Target$24.00 Potential Upside/Downside+25.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,670,000.00 Net Margins-44.45% Pretax Margin-44.32% Return on Equity0.94% Return on Assets0.75% Debt Debt-to-Equity RatioN/A Current Ratio5.93 Quick Ratio3.96 Sales & Book Value Annual Sales$166.88 million Price / Sales2.12 Cash Flow$4.78 per share Price / Cash Flow5.08 Book Value$14.50 per share Price / Book1.67Miscellaneous Outstanding Shares14,587,000Free Float13,440,000Market Cap$354.03 million OptionableOptionable Beta0.83 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:ANIK) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.